Merrimack Pharmaceuticals, Inc. (MACK) Stock Chart - Revenue & Earnings | Quarter Chart

📊 Income Statement

Revenue by Product

Revenue by Geography

Revenue, Gross Profit, Operating and Net Income

Margin (%)

Operating Expenses

Research And Development ExpensesSelling General And Administrative ExpensesOther Expenses
0112K225K338K450K562K675K788K900KQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024

EBITDA

EBITDA
-900K-738K-575K-412K-250K-88K75K238K400KQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024

EPS

Revenue Variation (%)

Revenue Variation
-200-175-150-125-100-74-49-241Q1 2023

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
02K5K8K10K12K15K18K20KQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Revenue YoY Variation (%)

Revenue YoY Variation
-200-175-150-125-100-74-49-241Q4 2023

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
04K8K11K15K19K22K26K30KQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Price-to-Earning Ratio

P/E Ratio
-600-525-450-375-300-224-149-741Q1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Income Breakdown

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
088K175K262K350K438K525K612K700KQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Per Share Metrics

Expense Ratios

💰 Cash Flow Statement

Operating Cash Flow

Free Cash Flow

Cash At End Of Period
038M75M112M150M188M225M262M300MQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024

Cash Flow to Debt Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
0250K500K750K1M1M2M2M2MQ1 2023Q2 2023Q3 2023Q4 2023Q1 2024
🏦 Balance Sheet
📈 Key Metrics